Abbott Laboratories has completed a $20 billion issuance of senior notes across various maturities to finance its acquisition of Exact Sciences Corporation and repay associated debt. This massive capital raise provides the liquidity needed for the merger but will significantly increase the company's long-term debt profile and introduces redemption risks if the deal fails to close by early 2027.
